Rigel Pharma (RIGL) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $1.14 +0.88%
EPS Growth %: +62.5%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
SFST, VLTO, CLIR, More
EPS Growth %: +62.5%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $8.9 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- KKR Real Estate Finance Trust (KREF) Tops Q1 EPS by 4c
- Chubb Corp. (CB) Tops Q1 EPS by 10c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
